Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Intermittent versus continuous androgen blockade]

J M Wolff1

  • 1Urologische Klinik, Universitätsklinikum, RWTH Aachen.

Der Urologe. Ausg. A
|May 1, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Evaluation of long-term effects after chemoprevention of prostate cancer].

Der Urologe. Ausg. A·2019
Same author

[Testosterone in the management of metastatic prostate cancer].

Der Urologe. Ausg. A·2015
Same author

[Value of intermittent androgen deprivation in the context of the current data situation].

Aktuelle Urologie·2013
Same author

[Pathophysiology and therapy of castration-resistant prostate cancer].

Der Urologe. Ausg. A·2012
Same author

Drivers for change in the management of prostate cancer - guidelines and new treatment techniques.

BJU international·2012
Same author

[Intermittent androgen deprivation in advanced prostate cancer: a review].

Aktuelle Urologie·2012
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
See all related articles

Intermittent androgen ablation therapy offers improved quality of life for advanced prostate cancer patients by reducing toxicity and costs. Further trials are needed to determine its impact on survival rates.

Area of Science:

  • Oncology
  • Urology
  • Medical Therapeutics

Context:

  • Advanced and metastatic prostate cancer treatment often involves androgen ablation.
  • Disease progression occurs within two years in over half of patients undergoing androgen ablation.
  • Intermittent androgen ablation (IAA) is an emerging therapeutic strategy.

Purpose:

  • To evaluate the efficacy and patient-reported outcomes of intermittent androgen ablation (IAA) for advanced prostate cancer.
  • To explore the potential benefits of IAA, including improved quality of life and delayed tumor progression.

Summary:

  • Intermittent androgen ablation involves cycling on and off medical castration to maintain cellular apoptotic potential.
  • This approach has demonstrated potential for improved patient quality of life due to reduced toxicity.

Related Experiment Videos

  • Cost savings and possible delays in tumor progression are additional reported benefits of IAA.

    • Impact:

    • IAA may offer a more tolerable treatment option for advanced prostate cancer, enhancing patient well-being.
    • Further clinical trials are essential to definitively assess the impact of IAA on overall survival.
    • This strategy could influence future treatment paradigms for hormone-sensitive prostate cancer.